Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 19Burkitt Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Lymphoma 7Neoplasms 5Lymphoma, Non-Hodgkin 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Leukemia, Biphenotypic, Acute 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Myasthenia Gravis 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1

Interventions

Cytarabine 7Cyclophosphamide 7Dexamethasone 6venetoclax 4blinatumomab 4Methotrexate 4Inotuzumab Ozogamicin 4pegaspargase 3merphos 3Vincristine 3Specimen Handling 3prednylidene 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2calaspargase pegol 2azathiopurine 2auricularum 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Calcium Dobesilate 2Biopsy 2Asparaginase 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Prednisone × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡